You see in the short-term list, on page 3, there's an item 7, clinical trial data protection. That has to do with prescription drugs. Then we have item 13 on the next page, national pharmaceutical strategy and patient access to prescription drugs. Then in item 15 we have the chairman's favourite, which is patient safety and adverse events. Those are three issues we might have one meeting around to see whether that whets our appetites, so that when we want to do a long-term study, we have some information to compare prescription drugs and wait lists.
Unfortunately, we don't have any way of having a sneak preview at childhood obesity, but that might be something we could look at if we get an extra meeting we don't know about, so that we're actually measuring those three topics from some knowledge base.